Study of primary cardiac lymphoma treated with anti-CD20 therapy
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial looks at people with lymphoma that involves mainly the heart (and possibly the lining around the heart) and was treated first with chemotherapy plus an anti-CD20 antibody. The goal is to understand outcomes from this specific treatment approach in patients diagnosed over a defined time period.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have primary cardiac lymphoma (a lymphoma in/around the heart only, possibly involving the heart’s lining).
- Your diagnosis was confirmed by biopsy/pathology, or (if biopsy wasn’t possible) special testing on heart lining fluid that matches the diagnosis—without using blood cell “one clone” results alone.
- Your lymphoma diagnosis date was between January 1, 2000 and December 31, 2020.
- Your first (initial) treatment was chemotherapy plus an anti-CD20 antibody.
- You can (or have) signed informed consent to take part.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three medicines (anti-PD-1, lenalidomide, and azacitidine) for adults with relapsed or refractory peripheral T-cell lymphoma (PTCL) that is measurable or growing. It aims to shrink lymphoma and improve control of the disease when standard treatments haven’t worked or have stopped working.
This trial studies the best way to use an early (frontline) stem cell transplant for high-risk, CD20-positive diffuse large B-cell lymphoma (DLBCL). It aims to improve outcomes by comparing treatment approaches designed for people with a higher risk score.
This trial tests a new experimental antibody therapy for people with certain types of peripheral T-cell lymphoma that have not responded to or have come back after prior treatment. The study aims to see if the treatment is safe and effective.
This trial is testing a new combination of immunotherapy (sintilimab and rituximab) followed by standard chemotherapy (R-CHOP) for people with untreated primary mediastinal B-cell lymphoma (PMBCL). It aims to see if this approach can improve outcomes for this specific type of lymphoma.
This trial tests if giving a tailored treatment after first complete remission can improve outcomes for certain types of peripheral T-cell lymphoma. It is for people who have finished initial standard chemotherapy with a complete response.
This study tests a new treatment that combines your own immune cells with a targeted drug and a stem cell transplant for a rare type of brain lymphoma. The goal is to see if this approach can help people whose cancer has returned or not fully responded to initial therapy.
Hear when a new Primary Cardiac Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.